Cigna Investments’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.48M | Sell |
11,734
-117
| -1% | -$15.4K | 0.19% | 86 |
|
|
2026
Q1 | $1.65M | Sell |
11,851
-168
| -1% | -$23.5K | 0.25% | 70 |
|
|
2025
Q4 | $1.48M | Sell |
12,019
-113
| -0.9% | -$13.7K | 0.21% | 86 |
|
|
2025
Q3 | $1.35M | Sell |
12,132
-150
| -1% | -$17.1K | 0.19% | 94 |
|
|
2025
Q2 | $1.36M | Sell |
12,282
-278
| -2% | -$29.6K | 0.23% | 80 |
|
|
2025
Q1 | $1.41M | Sell |
12,560
-174
| -1% | -$18K | 0.26% | 73 |
|
|
2024
Q4 | $1.18M | Sell |
12,734
-72
| -0.6% | -$6.48K | 0.21% | 95 |
|
|
2024
Q3 | $1.07M | Sell |
12,806
-338
| -3% | -$25.8K | 0.19% | 111 |
|
|
2024
Q2 | $902K | Sell |
13,144
-90
| -0.7% | -$6.01K | 0.17% | 121 |
|
|
2024
Q1 | $969K | Sell |
13,234
-70
| -0.5% | -$5.38K | 0.18% | 118 |
|
|
2023
Q4 | $1.08M | Sell |
13,304
-37
| -0.3% | -$2.88K | 0.22% | 100 |
|
|
2023
Q3 | $1M | Sell |
13,341
-1,898
| -12% | -$146K | 0.23% | 96 |
|
|
2023
Q2 | $1.18M | Sell |
15,239
-46
| -0.3% | -$3.67K | 0.22% | 97 |
|
|
2023
Q1 | $1.27M | Sell |
15,285
-311
| -2% | -$25.8K | 0.25% | 82 |
|
|
2022
Q4 | $1.34M | Buy |
15,596
+70
| +0.5% | +$5.54K | 0.28% | 76 |
|
|
2022
Q3 | $958K | Sell |
15,526
-574
| -4% | -$36.2K | 0.21% | 96 |
|
|
2022
Q2 | $995K | Sell |
16,100
-6,003
| -27% | -$372K | 0.2% | 105 |
|
|
2022
Q1 | $1.31M | Sell |
22,103
-6,121
| -22% | -$391K | 0.16% | 123 |
|
|
2021
Q4 | $2.05M | Sell |
28,224
-10,197
| -27% | -$702K | 0.16% | 106 |
|
|
2021
Q3 | $2.69M | Sell |
38,421
-824
| -2% | -$57.9K | 0.2% | 96 |
|
|
2021
Q2 | $2.7M | Sell |
39,245
-5,900
| -13% | -$394K | 0.19% | 100 |
|
|
2021
Q1 | $2.92M | Buy |
45,145
+1,391
| +3% | +$89.7K | 0.2% | 97 |
|
|
2020
Q4 | $2.55M | Buy |
43,754
+3,292
| +8% | +$199K | 0.2% | 100 |
|
|
2020
Q3 | $2.56M | Sell |
40,462
-142
| -0.3% | -$9.85K | 0.25% | 81 |
|
|
2020
Q2 | $3.13M | Buy |
40,604
+4,827
| +13% | +$370K | 0.3% | 69 |
|
|
2020
Q1 | $2.67M | Buy |
35,777
+2,150
| +6% | +$149K | 0.34% | 62 |
|
|
2019
Q4 | $2.13M | Sell |
33,627
-4,777
| -12% | -$311K | 0.22% | 88 |
|
|
2019
Q3 | $2.45M | Buy |
38,404
+2,507
| +7% | +$164K | 0.25% | 83 |
|
|
2019
Q2 | $2.35M | Sell |
35,897
-1,000
| -3% | -$65.8K | 0.26% | 81 |
|
|
2019
Q1 | $2.4M | Sell |
36,897
-989
| -3% | -$65.7K | 0.27% | 74 |
|
|
2018
Q4 | $2.37M | Buy |
37,886
+63
| +0.2% | +$4.4K | 0.2% | 75 |
|
|
2018
Q3 | $2.58M | Sell |
37,823
-3,474
| -8% | -$262K | 0.21% | 72 |
|
|
2018
Q2 | $2.92M | Sell |
41,297
-6,442
| -13% | -$455K | 0.21% | 68 |
|
|
2018
Q1 | $3.6M | Sell |
47,739
-2,510
| -5% | -$200K | 0.24% | 58 |
|
|
2017
Q4 | $3.6M | Sell |
50,249
-2,874
| -5% | -$218K | 0.24% | 55 |
|
|
2017
Q3 | $4.3M | Sell |
53,123
-293
| -0.5% | -$22.4K | 0.29% | 48 |
|
|
2017
Q2 | $3.78M | Sell |
53,416
-870
| -2% | -$57.9K | 0.26% | 51 |
|
|
2017
Q1 | $3.69M | Buy |
54,286
+5,558
| +11% | +$391K | 0.25% | 53 |
|
|
2016
Q4 | $3.49M | Buy |
+48,728
| New | +$3.62M | 0.38% | 50 |
|
Other funds holding GILD
Cigna Investments's GILD Position: Q2 2026 in Review
Cigna Investments reduced its Gilead Sciences (GILD) stake by 0.99% in Q2 2026, selling an estimated $15.4K and leaving 11,734 shares worth $1.48M. The position accounts for 0.19% of the portfolio, ranked #86.
Cigna Investments first reported a position in GILD in Q4 2016 and has held it in 39 quarters since. The position peaked at $4.3M in Q3 2017. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Cigna Investments held 11,734 shares of Gilead Sciences worth $1.48M as of Q2 2026.
- Cigna Investments sold 117 Gilead Sciences shares in Q2 2026, an estimated $15.4K.
- Gilead Sciences made up 0.19% of Cigna Investments's portfolio in Q2 2026, its #86 holding.
- Cigna Investments first reported a position in Gilead Sciences in Q4 2016 and has held it in 39 quarters since.
- Cigna Investments's Gilead Sciences position peaked at $4.3M in Q3 2017.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Cigna Investments's 13F filing for Q2 2026, filed 21 Jul 2026.